Claim · 2021-04-15 · publication · Stated in source · Supported

Recursion's IPO prospectus (15 April 2021) states that the company had four clinical stage programs and 33 additional programs in preclinical development.

One recorded claim. The claim panel gives its qualification, the source passages with their place in each source, and how it was checked.

What it connects

Recursion Pharmaceuticals, Inc. IPO prospectus (424B4) → states provision → company statement: four clinical stage programs (April 2021)

Where it appears

No collection page holds this claim. It is listed with its records in the explorer.

Claim and evidence

Recursion Pharmaceuticals, Inc. IPO prospectus (424B4)states provision ↓company statement: four clinical stage programs (April 2021)

Machine-checked, not reviewed by an editorStated in sourceSupported

Supporting evidence: primary · 1 source

Provision: Statement · provision ID co-recursion-clinical-programs-2021
Date: 2021-04-15 · publication Records dated 2021 →

Scope and limitsThe company's own count of its programs at the prospectus date; it does not establish trial phases, trial registrations or outcomes, and it does not state that each candidate was discovered by machine learning.

The evidence 01

primary sourceSupports the claim

Recursion Pharmaceuticals, Inc. prospectus (Rule 424(b)(4)), initial public offering of Class A common stock

Recursion Pharmaceuticals, Inc. (filed with the US SEC) · 2021-04-15

Cite the original source

Cite the original document, not Selekoa. Check these details against it.

Source excerpt

“We have four clinical stage programs and 33 additional programs in various stages of preclinical development.”

Location in source Risk factors

How it was read Retrieved directly from the publisher

Machine-checked · 2026-10-30

Source details and check notes

Authors: Recursion Pharmaceuticals, Inc. (filed with the US SEC)
Version: Retrieved for the candidate pack on 2026-10-30 (SHA-256 487039a60194b9c022cbf378210cd78655434c824bb3d7ae49f77ed721d01b4a). SEC EDGAR 424B4, accession 0001193125-21-119404, filed 2021-04-16; prospectus dated April 15, 2021; as served on 2026-10-30.
Canonical address: Open the canonical source ↗
Accessed: 2026-10-30
Language: English (en)
Attribution: Recursion Pharmaceuticals, Inc. (filed with the US SEC), “Recursion Pharmaceuticals, Inc. prospectus (Rule 424(b)(4)), initial public offering of Class A common stock”, 2021-04-15.
Reuse: No open redistribution licence asserted. Bibliographic metadata, editorial paraphrases and short attributed quotations (at most 50 words each). Recheck terms before wider redistribution.
Check notes: Candidate pack passage, AI in biology (research/ai-in-biology). The quotation (16 words) matched the text retrieved for the candidate pack on 2026-10-30. Matching ignored differences of whitespace, case, quotation marks, dashes and Unicode compatibility forms, so the source’s typography can differ. No human editorial review.

Status and meaning

Editorial status. Not reviewed by an editor. An exploratory record that no editor has accepted. This status does not say whether a person has read any linked passage. Each evidence record above shows how it was checked.

Relation. An exact framework edition, or another document with an exact expression, states one provision: a capability threshold or risk level and its trigger, a required safeguard or action, a decision authority (who decides, recommends, can overrule or is informed), a stated exception, or another statement of its content, such as a licence term or a prospectus statement. The passage records what the document says, not implementation, compliance or effectiveness. Provisions with the same key align across editions of one family.

Date. Prospectus date; the statement is a snapshot of the company's pipeline as it describes it.

Record ID aib-co-recursion-clinical-programs-2021